BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29398069)

  • 1. Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Naumann RW; Brown J
    Gynecol Oncol; 2018 Apr; 149(1):117-120. PubMed ID: 29398069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Menon U; McGuire AJ; Raikou M; Ryan A; Davies SK; Burnell M; Gentry-Maharaj A; Kalsi JK; Singh N; Amso NN; Cruickshank D; Dobbs S; Godfrey K; Herod J; Leeson S; Mould T; Murdoch J; Oram D; Scott I; Seif MW; Williamson K; Woolas R; Fallowfield L; Campbell S; Skates SJ; Parmar M; Jacobs IJ
    Br J Cancer; 2017 Aug; 117(5):619-627. PubMed ID: 28742794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating Cost-effectiveness of a Multimodal Ovarian Cancer Screening Program in the United States: Secondary Analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    Moss HA; Berchuck A; Neely ML; Myers ER; Havrilesky LJ
    JAMA Oncol; 2018 Feb; 4(2):190-195. PubMed ID: 29222541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
    Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
    Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of screening for ovarian cancer amongst postmenopausal women: a model-based economic evaluation.
    Kearns B; Chilcott J; Whyte S; Preston L; Sadler S
    BMC Med; 2016 Dec; 14(1):200. PubMed ID: 27919292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    Menon U; Ryan A; Kalsi J; Gentry-Maharaj A; Dawnay A; Habib M; Apostolidou S; Singh N; Benjamin E; Burnell M; Davies S; Sharma A; Gunu R; Godfrey K; Lopes A; Oram D; Herod J; Williamson K; Seif MW; Jenkins H; Mould T; Woolas R; Murdoch JB; Dobbs S; Amso NN; Leeson S; Cruickshank D; Scott I; Fallowfield L; Widschwendter M; Reynolds K; McGuire A; Campbell S; Parmar M; Skates SJ; Jacobs I
    J Clin Oncol; 2015 Jun; 33(18):2062-71. PubMed ID: 25964255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it?
    Havrilesky LJ; Sanders GD; Kulasingam S; Myers ER
    Gynecol Oncol; 2008 Nov; 111(2):179-87. PubMed ID: 18722004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
    Jacobs IJ; Menon U; Ryan A; Gentry-Maharaj A; Burnell M; Kalsi JK; Amso NN; Apostolidou S; Benjamin E; Cruickshank D; Crump DN; Davies SK; Dawnay A; Dobbs S; Fletcher G; Ford J; Godfrey K; Gunu R; Habib M; Hallett R; Herod J; Jenkins H; Karpinskyj C; Leeson S; Lewis SJ; Liston WR; Lopes A; Mould T; Murdoch J; Oram D; Rabideau DJ; Reynolds K; Scott I; Seif MW; Sharma A; Singh N; Taylor J; Warburton F; Widschwendter M; Williamson K; Woolas R; Fallowfield L; McGuire AJ; Campbell S; Parmar M; Skates SJ
    Lancet; 2016 Mar; 387(10022):945-956. PubMed ID: 26707054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.
    Skates SJ
    Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S24-6. PubMed ID: 22543916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Narod SA; Sopik V; Giannakeas V
    Gynecol Oncol; 2016 May; 141(2):191-194. PubMed ID: 26915499
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel risk models for early detection and screening of ovarian cancer.
    Russell MR; D'Amato A; Graham C; Crosbie EJ; Gentry-Maharaj A; Ryan A; Kalsi JK; Fourkala EO; Dive C; Walker M; Whetton AD; Menon U; Jacobs I; Graham RL
    Oncotarget; 2017 Jan; 8(1):785-797. PubMed ID: 27903971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalizing CA125 levels for ovarian cancer screening.
    Dorigo O; Berek JS
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1356-9. PubMed ID: 21893498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical approaches using longitudinal biomarkers for disease early detection: A comparison of methodologies.
    Han Y; Albert PS; Berg CD; Wentzensen N; Katki HA; Liu D
    Stat Med; 2020 Dec; 39(29):4405-4420. PubMed ID: 32939802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer screening--current status, future directions.
    Menon U; Griffin M; Gentry-Maharaj A
    Gynecol Oncol; 2014 Feb; 132(2):490-5. PubMed ID: 24316306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening.
    Pavlik EJ
    Womens Health (Lond); 2016 Sep; 12(5):475-479. PubMed ID: 27595999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to the detection of ovarian cancer.
    Høgdall E
    Scand J Clin Lab Invest Suppl; 2016; 245():S49-53. PubMed ID: 27435369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis.
    Marchetti C; De Felice F; Perniola G; Lecce F; Vertechy L; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
    Curr Probl Cancer; 2018; 42(2):235-240. PubMed ID: 29433824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economics of screening for gynaecological cancers.
    Kulasingam S; Havrilesky L
    Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):163-73. PubMed ID: 22138003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.
    Havrilesky LJ; Sanders GD; Kulasingam S; Chino JP; Berchuck A; Marks JR; Myers ER
    Cancer; 2011 Feb; 117(3):545-53. PubMed ID: 21254049
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.